Replies to post #88185 on Cytodyn Inc (CYDY)

[SaraLovesYou]

Actually five trials are currently recruiting for BMS813160 for various cancers as a combo therapy. Medical folks - can you speak to how this compares to Leronlimab? To recap, BMS813160 targets CCR2/CCR5. Certainly there will be other comparable such as 1L-6 inhibition, etc.

Active trial links: https://clinicaltrials.gov/ct2/results?cond=&term=BMS813160+&type=&rslt=&recrs=a&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=


>>>>>
The only active clinical trial for BMS drug is scheduled for completion in 2015. The other two trials were closed out a few years ago.


Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT03496662 Washington University School of Medicine|Bristol-Myers Squibb|Barnes-Jewish Hospital|National Institutes of Health (NIH)|National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma
August 31, 2018 Phase 1|Phase 2
NCT01049165 Bristol-Myers Squibb
Accelerated Intimal Hyperplasia
February 2010 Phase 1
NCT01752985 Bristol-Myers Squibb
Diabetic Kidney Disease
March 18, 2013 Phase 2